The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Regeneron
Stock and Other Ownership Interests - Bristol-Myers Squibb; Regeneron
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb
A study of REGN3767, an anti-LAG-3 antibody, alone and in combination with cemiplimab (REGN2810), an anti-PD1 antibody in advanced cancers.
 
Kyriakos P. Papadopoulos
Consulting or Advisory Role - ArQule (Inst); Bayer (Inst)
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); ArQule (Inst); Calithera Biosciences (Inst); Curegenix (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Formation Biologics (Inst); Incyte (Inst); Jounce Therapeutics (Inst); MabSpace Biosciences (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); OncoMed (Inst); Peloton Therapeutics (Inst); Regeneron (Inst); Sanofi (Inst); Syros Pharmaceuticals (Inst)
 
Nehal Lakhani
No Relationships to Disclose
 
Melissa Lynne Johnson
Consulting or Advisory Role - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Celgene (Inst); Genentech/Roche (Inst); Loxo (Inst); Merck (Inst); Mirati Therapeutics (Inst); Otsuka (I); Sanofi (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BeiGene (Inst); BerGenBio (Inst); Birdie (Inst); Boehringer Ingelheim (Inst); Checkpoint Therapeutics (Inst); Corvus Pharmaceuticals (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Foundation Medicine (Inst); Genmab (Inst); Genocea Biosciences (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Hengrui Pharmaceutical (Inst); Incyte (Inst); Janssen (Inst); Kadmon (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Sanofi (Inst); Stem CentRx (Inst); Tarveda Therapeutics (Inst)
 
Haeseong Park
Research Funding - Ambrx (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Roche (Inst); Taiho Pharmaceutical (Inst); Vertex (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Bayer
 
Ding Wang
Consulting or Advisory Role - Merck
Travel, Accommodations, Expenses - Merck
 
Timothy A. Yap
Honoraria - AstraZeneca
Consulting or Advisory Role - Aduro Biotech; AstraZeneca; Atrin Pharmaceuticals; Clovis Oncology; EMD Serono; Ignyta; Janssen; Merck; Pfizer; Tesaro
Speakers' Bureau - AstraZeneca
Research Funding - AstraZeneca; Clearbridge Biomedics; Pfizer; Roche; Vertex
Patents, Royalties, Other Intellectual Property - Employee of The Institute of Cancer Research, which has a financial interest in the discovery and development of anticancer drugs (Inst)
Travel, Accommodations, Expenses - Vertex
 
Kathleen N. Moore
Consulting or Advisory Role - Advaxis; Aravive; AstraZeneca; Clovis Oncology; Genentech/Roche; Immunogen; Janssen Oncology; Merck; TESARO; VBL Therapeutics
Research Funding - Clovis Oncology (Inst); Genentech (Inst); Lilly (Inst); Merck (Inst); PTC Therapeutics (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
Other Relationship - AstraZeneca
 
Tasha Nicholle Sims
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - Regeneron
Travel, Accommodations, Expenses - Regeneron
 
Chetachi A. Emeremni
Employment - Regeneron
 
Maria Karasarides
Employment - AstraZeneca/MedImmune; Regeneron
Stock and Other Ownership Interests - AstraZeneca/MedImmune; Regeneron
Research Funding - AstraZeneca/MedImmune; Regeneron
Patents, Royalties, Other Intellectual Property - Declaration PCT Application No: PCT/US2017/025246: Combinations of an anti-BR-H1 antibody and a CXCR4 peptide antagonist for treating a solid tumor.; Declaration PCT Application No: PCT/US2017/058684: Combination of anti-VEGFR2 antibody and an anti-PD-L1 antibody for the treatment of cancer.
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Regeneron
 
Glenn S. Kroog
No Relationships to Disclose